Key result
Fuzheng Yangxin Granule will be evaluated for its efficacy and safety in improving exercise capacity among 150 patients with heart failure with preserved ejection fraction in a planned randomized controlled trial.
Why the study?
Few clinical trials use rigorous methodologies to evaluate the efficacy and safety of traditional Chinese medicine for heart failure with preserved ejection fraction.
Does Fuzheng Yangxin Granule improve maximal peak oxygen uptake in patients with HFpEF and Qi-Yin deficiency and blood stasis syndrome?
RCT (n=150)
Double-blind
Blocked randomization
Yes
Does Fuzheng Yangxin Granule improve maximal peak oxygen uptake in patients with HFpEF and Qi-Yin deficiency and blood stasis syndrome?
This study protocol describes a planned multicenter RCT to evaluate whether Fuzheng Yangxin Granule improves peak oxygen uptake in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
Does not yet support Fuzheng Yangxin Granule in HFpEF; RCT will clarify efficacy on peak VO2.
Introduction Heart failure with preserved ejection fraction (HFpEF) is a widespread public health issue worldwide. Despite recent advances in pharmacologic treatments and the introduction of new diagnostic approaches, HFpEF remains underdiagnosed and under-recognized in clinical practice. Traditional Chinese medicine (TCM) may offer a potentially effective treatment for HFpEF. Nevertheless, few clinical trials employ rigorous research methodologies to evaluate the efficacy and safety of TCM in treating HFpEF. Consequently, we propose to assess the hypothesis that patients with HFpEF may benefit from Fuzheng Yangxin Granule (FZYX) and evaluate its safety in a rigorously designed clinical trial. Methods This multicenter, double-blind, randomized controlled trial will be conducted across seven tertiary hospitals in China. We will enroll 150 participants aged 18–80 years with confirmed HFpEF (Qi-Yin deficiency and blood stasis syndrome) meeting inclusion criteria. Participants will be randomly assigned (1:1) to the FZYX group or the placebo group, with both groups receiving standardized Western medical therapy according to the National Heart Failure Guideline 2023. The 12-week intervention phase will be followed by 40-week safety follow-up. The primary outcome will be maximal peak oxygen uptake (peak VO 2 ). Secondary outcomes will include composite endpoint events, all-cause mortality, 6-minute walking distance (6MWD), New York Heart Association (NYHA) functional class, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiographic variables, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, TCM syndrome scores, and the FRAIL scale. Discussion The objective of this study is to evaluate the efficacy and safety of FZYX in treating HFpEF (Qi-Yin deficiency and blood stasis syndrome), thereby providing a high-quality, reliable evidence-based foundation for clinical practice. Clinical Trial Registration China Clinical Trial Registry (ChiCTR2400087293), Registered on July 24, 2024.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) (n=150). Fuzheng Yangxin Granule vs. Placebo was evaluated on Maximal peak oxygen uptake (peak VO2). Fuzheng Yangxin Granule will be evaluated for its efficacy and safety in improving exercise capacity among 150 patients with heart failure with preserved ejection fraction in a planned randomized controlled trial.
Synapse has enriched 10 related papers. Consider them for comparative context: